T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma

J Invest Dermatol. 2018 Jun;138(6):1442-1445. doi: 10.1016/j.jid.2017.12.027. Epub 2017 Dec 29.
No abstract available

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Biopsy
  • Female
  • Follow-Up Studies
  • Humans
  • Imiquimod / administration & dosage
  • Injections, Intralesional
  • Interleukin-2 / administration & dosage
  • Male
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Melanoma / pathology
  • Middle Aged
  • Retinoids / administration & dosage
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology*
  • Treatment Outcome

Substances

  • Interleukin-2
  • Retinoids
  • Imiquimod